Agomab grants director 57K options at $13.94

A director of Agomab Therapeutics NV received a new 57,482-share stock option grant at a $13.94 exercise price with long-term vesting conditions.

Rhea-AI Filing Summary

Agomab Therapeutics NV (AGMB) reported that director Garcia Marino received a grant of 57,482 stock options on September 11, 2026. The options have an exercise price of $13.94 per common share, expire on January 15, 2036, and relate to common shares that may be represented by American Depositary Shares.

According to the vesting terms, 33% of the shares underlying this option vest on September 11, 2027, with the remaining options vesting in 24 equal monthly installments thereafter, subject to continued service. No Rule 10b5-1 trading plan is reported for this award.

Insider Trade Summary

Grant/Award: 57,482 shares

Grant/Award 1 txn

Insider Garcia Marino

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2, F3	57,482	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 57,482 contracts (Direct)

Footnotes (3)

1. F1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
2. F2. The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.
3. F3. 33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Stock options granted: 57,482 options Exercise price: $13.94 per common share Underlying common shares: 57,482 shares +5 more

8 metrics

Stock options granted 57,482 options Grant to director Garcia Marino on September 11, 2026

Exercise price $13.94 per common share Exercise price of the stock option grant

Underlying common shares 57,482 shares Shares underlying the reported stock option grant

Vesting cliff 33% on September 11, 2027 Initial vesting portion of the option award

Remaining vesting schedule 24 equal monthly installments Remainder of vesting after September 11, 2027

Expiration date January 15, 2036 Expiration of the stock options granted

FX exchange rate $1.1616 per EUR 1.00 Rate used to convert exercise price from EUR to USD

ADS to common share ratio 1 ADS : 1 common share Common shares may be represented by American Depositary Shares

Key Terms

American Depositary Shares, exercise price, vesting, exchange rate

4 terms

American Depositary Shares financial

"The common shares may be represented by American Depositary Shares, each of which"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

exercise price financial

"The exercise price is reported in U.S. dollars and reflects the conversion"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exchange rate financial

"reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR"

Exchange rate is the price of one currency expressed in another—for example, how many euros you receive for one US dollar. It matters to investors because changes in that price alter the reported profits, costs and value of assets for companies and portfolios that operate or hold money across borders; think of it like switching measurement units, where the same item can look bigger or smaller depending on the unit used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AGMB report for director Garcia Marino?

AGMB reported that director Garcia Marino received a grant of 57,482 stock options on September 11, 2026, with an exercise price of $13.94 per common share and an expiration date of January 15, 2036.

What are the vesting terms of the new stock options reported by AGMB?

For AGMB, 33% of the shares underlying Garcia Marino’s option vest on September 11, 2027, and the remaining shares vest in 24 equal monthly installments afterward, subject to continued service on each vesting date.

How many shares underlie the new stock option grant at AGMB?

The stock option grant to director Garcia Marino at AGMB covers 57,482 common shares, which may be represented by American Depositary Shares, each currently representing one common share.

What is the exercise price and currency basis of the AGMB option grant?

The exercise price of the AGMB option grant is $13.94 per common share, reported in U.S. dollars and reflecting a conversion from euros at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.

When do the newly granted AGMB options expire?

The newly granted stock options to AGMB director Garcia Marino expire on January 15, 2036, providing a long-term window to exercise once the options are vested.

Were the AGMB insider option grants made under a Rule 10b5-1 plan?

No. The filing for AGMB indicates that no Rule 10b5-1 trading plan is reported in connection with this stock option grant to director Garcia Marino.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:07 PM Accepted by SEC EDGAR 09/15/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garcia Marino

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Issuer Name and Ticker or Trading Symbol
AgomAb Therapeutics NV [ AGMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.94(1)	09/11/2026		A		57,482		(2)	01/15/2036	Common shares(3)	57,482	$0.00	57,482	D

Explanation of Responses:

1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

2. The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.

3. 33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Ellen Lefever, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)